Literature DB >> 19824189

Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis.

Marc Jeuland1, Joseph Cook, Christine Poulos, John Clemens, Dale Whittington.   

Abstract

OBJECTIVES: We evaluated the cost-effectiveness of a low-cost cholera vaccine licensed and used in Vietnam, using recently collected data from four developing countries where cholera is endemic. Our analysis incorporated new findings on vaccine herd protective effects.
METHODS: Using data from Matlab, Bangladesh, Kolkata, India, North Jakarta, Indonesia, and Beira, Mozambique, we calculated the net public cost per disability-adjusted life year avoided for three immunization strategies: 1) school-based vaccination of children 5 to 14 years of age; 2) school-based vaccination of school children plus use of the schools to vaccinate children aged 1 to 4 years; and 3) community-based vaccination of persons aged 1 year and older.
RESULTS: We determined cost-effectiveness when vaccine herd protection was or was not considered, and compared this with commonly accepted cutoffs of gross domestic product (GDP) per person to classify interventions as cost-effective or very-cost effective. Without including herd protective effects, deployment of this vaccine would be cost-effective only in school-based programs in Kolkata and Beira. In contrast, after considering vaccine herd protection, all three programs were judged very cost-effective in Kolkata and Beira. Because these cost-effectiveness calculations include herd protection, the results are dependent on assumed vaccination coverage rates.
CONCLUSIONS: Ignoring the indirect effects of cholera vaccination has led to underestimation of the cost-effectiveness of vaccination programs with oral cholera vaccines. Once these effects are included, use of the oral killed whole cell vaccine in programs to control endemic cholera meets the per capita GDP criterion in several developing country settings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824189     DOI: 10.1111/j.1524-4733.2009.00562.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  39 in total

1.  Forecasting the economic value of an Enterovirus 71 (EV71) vaccine.

Authors:  Bruce Y Lee; Angela R Wateska; Rachel R Bailey; Julie H Y Tai; Kristina M Bacon; Kenneth J Smith
Journal:  Vaccine       Date:  2010-10-16       Impact factor: 3.641

Review 2.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

3.  Social and cultural determinants of oral cholera vaccine uptake in Zanzibar.

Authors:  Christian Schaetti; Said M Ali; Raymond Hutubessy; Ahmed M Khatib; Claire-Lise Chaignat; Mitchell G Weiss
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

4.  Vaccination strategies for epidemic cholera in Haiti with implications for the developing world.

Authors:  Dennis L Chao; M Elizabeth Halloran; Ira M Longini
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

Review 5.  Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries.

Authors:  John Clemens
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

Review 6.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

Review 7.  Systematic review of the economic value of diarrheal vaccines.

Authors:  Richard Rheingans; Mirna Amaya; John D Anderson; Poulomy Chakraborty; Jacob Atem
Journal:  Hum Vaccin Immunother       Date:  2014-05-27       Impact factor: 3.452

Review 8.  Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.

Authors:  Sachin N Desai; Alejandro Cravioto; Dipika Sur; Suman Kanungo
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 9.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

Review 10.  Modeling cholera outbreaks.

Authors:  Dennis L Chao; Ira M Longini; J Glenn Morris
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.